| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5563175 | UPJOHN | GABA and L-glutamic acid analogs for antiseizure treatment |
Oct, 2013
(10 years ago) | |
| US6197819 | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Dec, 2018
(5 years ago) | |
| US6001876 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
| USRE41920 | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Dec, 2018
(5 years ago) | |
|
USRE41920 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(4 years ago) | |
|
US6001876 (Pediatric) | UPJOHN | Isobutylgaba and its derivatives for the treatment of pain |
Jun, 2019
(4 years ago) | |
|
US6197819 (Pediatric) | UPJOHN | Gamma amino butyric acid analogs and optical isomers |
Jun, 2019
(4 years ago) | |
Lyrica is owned by Upjohn.
Lyrica contains Pregabalin.
Lyrica has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Lyrica are:
- US5563175
- US6197819
- US6001876
- USRE41920
- USRE41920*PED
- US6001876*PED
- US6197819*PED
Lyrica was authorised for market use on 30 December, 2004.
Lyrica is available in capsule;oral, solution;oral dosage forms.
Lyrica can be used as treatment of pain, including neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, and fibromyalgia, treatment of seizure disorder, management of fibromyalgia.
The generics of Lyrica are possible to be released after 23 November, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-193) | Dec 22, 2019 |
| Pediatric Exclusivity(PED) | Nov 23, 2022 |
| New Patient Population(NPP) | May 23, 2022 |
| New Indication(I-651) | Jun 20, 2015 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 30 December, 2004
Treatment: Treatment of seizure disorder; Management of fibromyalgia; Treatment of pain, including neuropathic pain associated with diabetic peripheral neuropathy or spinal cord injury, postherpetic neuralgia, a...
Dosage: CAPSULE;ORAL; SOLUTION;ORAL
LYRICA family patents
